Company intelligence / Profile preview
GentiBio
Cambridge, Massachusetts, USAgentibio.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
GentiBio has developed a modular engineering platform to create potent, stable, and targeted engineered regulatory T cells. Their programs are in preclinical development targeting autoimmune and inflammatory conditions. No clinical results have been reported yet as of May 2025.
- Therapeutic areas
- PulmonologyEndocrinologyImmunologyGastroenterology
- Modalities
- Engineered regulatory T cells (EngTregs)Cell therapy
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
Beyond the preview
Go deeper on GentiBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GentiBio.